Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scleroderma. Clinical problems. The lungs

R M Silver1

  • 1Division of Rheumatology and Immunology Medical University of South Carolina, Charleston 29425-2229, USA.

Rheumatic Diseases Clinics of North America
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modified Delphi study of ultrasound signs associated with placenta accreta spectrum.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2023
Same author

PACK syndrome: A case series and review.

The American journal of the medical sciences·2022
Same author

Debunking 20<sup>th</sup> century myths and legends about the diagnosis of placenta accreta spectrum.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2022
Same author

Maternal serum fructosamine levels and stillbirth: a case-control study of the Stillbirth Collaborative Research Network.

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Preventable stillbirths in India and Pakistan: a prospective, observational study.

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Placenta accreta spectrum: welcome progress and a call for standardisation.

BJOG : an international journal of obstetrics and gynaecology·2021
Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
See all related articles

Systemic sclerosis (SSc) lung disease, particularly interstitial lung disease, has high mortality. Understanding its fibrotic and vascular pathways is key to developing new treatments for SSc patients.

Area of Science:

  • Rheumatology
  • Pulmonology
  • Pathophysiology

Background:

  • Systemic sclerosis (SSc) lung disease contributes significantly to mortality.
  • Pulmonary hypertension is a frequent cause of death in SSc patients.
  • Interstitial lung disease (ILD) in SSc arises from inflammatory and fibrosing mediators.

Purpose of the Study:

  • To review current understanding of SSc lung disease pathophysiology.
  • To highlight the role of fibrogenic cytokines and vascular mediators.
  • To emphasize the need for improved diagnostics and therapeutics.

Main Methods:

  • Review of recent follow-up and mortality studies in SSc.
  • Analysis of the inflammatory and fibrotic pathways in SSc lung disease.
  • Examination of the role of cytokines like PDGF and TGF-beta.

Related Experiment Videos

  • Investigation of mediators of vascular tone, including endothelin and nitric oxide.

    • Main Results:

    • Patients with SSc and pulmonary involvement survived a median of 78 months.
    • Pulmonary hypertension is the most common cause of death in SSc.
    • Fibrogenic cytokines (PDGF, TGF-beta) and vascular mediators (endothelin, nitric oxide) are implicated in SSc lung disease.

    Conclusions:

    • High mortality from SSc lung disease necessitates improved diagnostic and therapeutic strategies.
    • Targeting fibrogenic cytokines and vascular mediators offers potential for novel treatments.
    • Further research into the pathophysiology of SSc lung disease is crucial for patient survival.